Skip to main content

Cognitive Disorders

5
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Medica Corp
Medica CorpMA - Bedford
1 program
1
MMH-MAPPhase 31 trial
Active Trials
NCT04295681Completed246Est. Feb 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
GSK1034702Phase 1
GSK1034702Phase 1
GSK1043702Phase 1
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
SDI-118Phase 11 trial
Active Trials
NCT05486195Completed32Est. Mar 2020
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV DrugsN/A1 trial
Selegiline hydrochlorideN/A1 trial
Active Trials
NCT00001103Completed100
NCT00027040Completed90Est. Jun 2005
Ipsen
IpsenChina - Tianjin
1 program
EGb761®N/A1 trial
Active Trials
NCT02321475Completed54Est. Apr 2015
GSK
GSKLONDON, United Kingdom
1 program
GSK1034702PHASE_11 trial
Active Trials
NCT00937846Completed4Est. Aug 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Medica CorpMMH-MAP
AbbVieSDI-118
GSKGSK1034702
Allergy TherapeuticsSelegiline hydrochloride
IpsenEGb761®

Clinical Trials (6)

Total enrollment: 526 patients across 6 trials

NCT04295681Medica CorpMMH-MAP

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders

Start: Dec 2019Est. completion: Feb 2023246 patients
Phase 3Completed
NCT05486195AbbVieSDI-118

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

Start: Mar 2019Est. completion: Mar 202032 patients
Phase 1Completed
NCT00937846GSKGSK1034702

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

Start: Jul 2009Est. completion: Aug 20094 patients
Phase 1Completed
NCT00001103Allergy TherapeuticsHIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

100 patients
N/ACompleted
NCT00027040Allergy TherapeuticsSelegiline hydrochloride

A Study of Decreased Mental Function Associated With HIV

Est. completion: Jun 200590 patients
N/ACompleted
NCT02321475IpsenEGb761®

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

Start: Jun 2014Est. completion: Apr 201554 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.